Skip to Content Facebook Feature Image

Insta360 Unveils GO Ultra: The Pocket Camera for Capturing Life as You Live it

Business

Insta360 Unveils GO Ultra: The Pocket Camera for Capturing Life as You Live it
Business

Business

Insta360 Unveils GO Ultra: The Pocket Camera for Capturing Life as You Live it

2025-08-21 21:00 Last Updated At:21:15

LOS ANGELES, Aug. 21, 2025 /PRNewswire/ -- Insta360 is proud to reveal GO Ultra, the latest evolution in the world of compact cameras. Still tiny, still hands-free, now with serious power for superior image quality.

 
Meet Insta360 GO Ultra - The Tiny 4K Cam Built for the Moment

 
Meet Insta360 GO Ultra - The Tiny 4K Cam Built for the Moment

"GO Ultra takes the advancements made with the Ace and X series cameras, and puts them into the type of compact, pocket camera our GO Series creators enjoy," said Insta360 Co-Founder and VP of Marketing, Max Richter, "opening up new creative opportunities without sacrificing portability."

The 1/1.28" sensor, which is 221% larger than its predecessor, and new 5nm AI chip deliver imaging previously impossible in the GO series. Ultra-smooth, ultra-crisp 4K60fps video is the new cinematic standard for pocket cameras, and creative limits are pushed even further by PureVideo, which uses cutting-edge AI algorithms to reduce visual noise and enhance brightness in low light.

At just 53g, the size of a smartwatch, and with a built-in magnetic base, you can mount the GO Ultra Standalone Camera anywhere and capture angles other cameras can only dream of. With an upgraded Magnet Pendant and a vast array of new accessories, from the peel-and-use Sticky Tabs to the wholly original Toddler Titan Hat Clip, a new world of immersive shooting awaits.

Just as intuitive is the upgraded Insta360 app, with powerful AI tools to instantly turn your footage into shareable content. Transitions, effects, music, and more can be added with just a few taps. Cyclists can add their data—GPS, heart rate, speed—from Strava or a third-party device that syncs in real-time to their footage. The new AI Family Moments feature collates all your loved ones' magic moments into a virtual album to cherish forever.

GO Ultra's blend of heavyweight power, lightweight portability, and ease of use makes it essential for vloggers with active lifestyles, families sharing milestones, or travelers searching for new horizons—people who live in the moment.

Insta360 GO Ultra goes on sale August 21, 2025, at the Insta360 Store, Amazon, and select retailers worldwide. The Standard Bundle is priced at US$449.99 and includes GO Ultra (Standalone Camera and Action Pod) in either Midnight Black or Arctic White, a Quick Release Safety Cord, Magnetic Easy Clip, Magnet Pendant, USB-C cable, and a Lens Guard.

About Insta360  

With a "Think bold" mindset, Insta360 empowers people to capture and share their lives in extraordinary ways. Recognized as a market leader and innovator, Insta360's vast lineup includes the world's best-selling 360 cameras in the X Series, the thumb-sized GO Series for everyday capture, as well as an extensive range of action cameras, gimbals, webcams, and professional photography solutions. With intuitive, AI-powered software, Insta360 simplifies the creative process, allowing users to focus on storytelling without technical barriers. Insta360 is dedicated to helping a new generation of athletes, creatives, travelers and professionals bring their ideas to life.

For more details visit: http://www.insta360.com
About the Think Bold Fund: https://www.insta360.com/ThinkBoldFund
Read our blog: https://www.insta360.com/blog
Follow us on Facebook: https://www.facebook.com/Insta360
Follow us on X: https://x.com/insta360
Follow us on Instagram: http://www.instagram.com/insta360
Follow us on TikTok: http://tiktok.com/@insta360_official
Follow us on LinkedIn: https://www.linkedin.com/company/insta360
Subscribe to our YouTube Channel: http://www.youtube.com/insta360

Press Contact

Max Richter
Insta360
pr@insta360.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Insta360 Unveils GO Ultra: The Pocket Camera for Capturing Life as You Live it

Insta360 Unveils GO Ultra: The Pocket Camera for Capturing Life as You Live it

FREMONT, Calif., Jan. 13, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This innovative solution enables simultaneous quantitative measurement of five critical blood-based biomarkers relevant to the Alzheimer's Association recommended guidelines: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4 (carrier status), all from a single blood or plasma sample.

The NULISAqpcr AD 5-plex Assay consolidates key biomarkers into a single multiplexed format, delivering unmatched sensitivity, specificity, and ease of use. By incorporating BD-pTau217, Aβ42, NfL, and GFAP, the assay enables robust monitoring of amyloid and tau pathology, neurodegeneration, and inflammation, while accurately determining APOE4 carrier status—the strongest genetic risk factor for Alzheimer's disease. Together, these capabilities create a powerful tool for both translational and clinical research, and its relevance extends beyond Alzheimer's disease to other neurodegenerative and cognitive disorders.

"The launch of the NULISAqpcr AD 5-plex Assay marks a significant milestone in our efforts to deliver precision proteomics solutions for neurodegenerative disease," said Dr. Yuling Luo, founder, chairman and chief executive officer of Alamar. "By combining these critical protein targets into a single assay with a streamlined workflow, we are empowering the neuroscience community to advance screening, early detection and precision diagnoses for Alzheimer's disease."

"Blood-based biomarkers are redefining Alzheimer's research, providing an accurate, cheaper and more accessible means of establishing early diagnosis and aiding determination of eligibility for therapies," said Dr. Steven Williams, chief scientific officer of Alamar. "Traditional single-plex assays can measure these biomarkers individually, but require multiple tests to provide a comprehensive view of the disease. With NULISA™ it is now possible to measure multiple Alzheimer's-related proteins in blood, each offering unique insights into the underlying pathophysiology."

Alamar is dedicated to collaborating with researchers, clinicians, and industry partners to unlock precision proteomics and improve outcomes for patients affected by Alzheimer's disease and other neurodegenerative conditions. The NULISAqpcr AD 5-plex Assay is available today as a service through our Technology Access Program.

For more information about the NULISAqpcr AD 5-plex Assay and Alamar's full portfolio of precision proteomic solutions, visit www.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research

Recommended Articles